Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Morris

Gastroenterology Baltimore, MD Medical Doctor

NPI 1912224957 CMS profile 759606

22 S Greene St, Baltimore, MD 21201

Open in the dashboard

General payments

$21,855

63 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,565 paid to institutions, not to them · program year 2019

Through program year 2025, John Morris of Baltimore, MD is reported in the CMS Open Payments database as having received $21,855 across 63 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,565 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $255 5
2024 General $575 12
2023 General $17,448 23
2022 General $2,505 18
2019 General $1,073 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Morris
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to John Morris were reported at $255. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year John Morris Gastroenterology median Middle half National median
2019 $1,073 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $2,505 $448 $129–$1,270 $149
2023 $17,448 $533 $150–$1,390 $160
2024 $575 $605 $160–$1,606 $164
2025 $255 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $20,053 55 payments
  2. Olympus Corporation of the Americas $1,013 6 payments
  3. Merit Medical Systems Inc $700 1 payment
  4. Medtronic, Inc. $89 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,625 4 payments
  2. Consulting Fee $5,375 3 payments
  3. Travel and Lodging $4,478 14 payments
  4. Food and Beverage $1,378 42 payments
Products named General payments · program years 2019–2025
  1. ORISE $1,374 5 payments
  2. Single Use Aspiration Needle NA-U200H $1,013 6 payments
  3. General - Therapies $1,001 4 payments
  4. General Therapies $954 4 payments
  5. EXALT Model D EXALT Model D_ENDO $119 4 payments
  6. ACQUIRE $118 1 payment
  7. SharkCore $89 1 payment
  8. EXALT Model D Exalt_Endo $77 4 payments
  9. General - Polypectomy $60 3 payments
  10. Agile Esophageal $46 3 payments
  11. Other $153 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

37

Median for Gastroenterology: 569

Drug cost

$121

Median for Gastroenterology: $104,976

Branded share of claims

0%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 12 $80
Levofloxacin Generic 25 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$78,930

Medicare's payments for the services billed

Medicare patients

233

Average age 72

Services billed

638

114 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 45%
Diabetes 34%
Ischemic heart disease 27%
Depression 26%
Cancer 24%
Chronic kidney disease 23%
Atrial fibrillation 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record